24/7 Delivery

The new service every Houston shopper and small business needs to know about

Welcome to Houston, Lalamove. Photo by @HoustonTips

Holiday shopping is in full swing, and the bane of everyone's existence — especially during a pandemic — is shipping.

For smaller and mid-sized local businesses, that means paying big-business prices to a national shipping company. And for consumers, it's waiting a week or more to receive your item, even if you paid for shipping.

Lalamove has a solution for both parties. The 24/7 on-demand delivery app recently launched in Houston and offers affordable, same-day delivery services for the local merchants we're all trying to support right now.

"Amidst COVID-19, it is more important than ever to shop local and support our small businesses," says Lalamove's international managing director, Blake Larson. "We look forward to providing our services to Houston businesses in need of a fruitful start to the holiday season."

Unlike other delivery options, Lalamove delivers everything from food to small packages to bulky furniture within the same day, and it operates on a base-plus-miles pricing model with no commissions.

Deliveries in a sedan start at $8.90, with $1 per additional mile. SUV pricing has a base fare of $16.90 plus $1.25 per mile. Other same-day delivery options with national shipping companies can be well over $100 dollars, depending on the size and weight of the package.

Neighborhood-to-neighborhood sedan pricing is more affordable than traditional same-day shipping: Museum District to Midtown is $9.90, Midtown to The Heights is $14.90, and Northside to East Downtown is $17.90.

This also contrasts with food delivery platforms that charge restaurants 15-30 percent commission on the entire order; with Lalamove, the delivery charge for a $25 meal is the same as a $150 meal.

Users and businesses can place an order via the Lalamove app or on its website, which is available 24/7. When placing your order, you are instantly matched with a driver and their car, based on your delivery needs. You can deliver to (or order from) up to 20 locations in one order with the multi-stop delivery feature, and can schedule a delivery in advance or book for right then.

Lalamove appUsing Lalamove is simple. Graphic courtesy of Lalamove

Shoppers can request Lalamove's services with local boutiques and stores that don't normally offer delivery, and get instant gratification (and a much smoother holiday season) with same-day delivery.

Both sides can rest easy knowing that things will arrive in time for the holidays in a trusted, secure, and quick fashion.

To help small businesses provide fast, reliable delivery throughout the holidays, Lalamove is offering $10 off with promo code LACMHOU10. Business owners can try out the service, or customers can take advantage of Lalamove if they need delivery.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted